Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer Journal Article
| Authors: | Myskowski, P. L.; Halpern, A. C. |
| Article Title: | Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer |
| Abstract: | Advances in molecular biology have led to the successful development of targeted monoclonal antibodies to several types of malignancies. By June 2007, nine therapeutic monoclonal antibodies had been approved by the US Food and Drug Administration to treat various human cancers. In general, the adverse reactions of these agents have been milder than their cytotoxic chemotherapy counterparts, but side effects do occur. Cutaneous adverse reactions to the first of these agents were rare, and primarily limited to infusion reactions, local inflammation at injection sites, and ill-defined transient eruptions. However, the use of monoclonal antibody therapy against the epidermal growth factor receptor-1 in gastrointestinal and head and neck cancer has been frequently associated with significant skin reactions. As the use of these agents becomes more widespread, the recognition and management of these skin reactions becomes an increasingly important part of patient care. © 2009 Current Medicine Group, LLC. |
| Keywords: | unclassified drug; acute granulocytic leukemia; prednisone; review; squamous cell carcinoma; bevacizumab; doxorubicin; fluorouracil; advanced cancer; side effect; skin toxicity; solid tumor; skin manifestation; paclitaxel; cancer radiotherapy; ibritumomab tiuxetan; rituximab; antineoplastic agent; neoplasm; colorectal cancer; carboplatin; unindexed drug; edema; breast cancer; bone marrow suppression; skin defect; nausea; cyclophosphamide; vincristine; herpes zoster; cetuximab; cancer therapy; b lymphocyte; irinotecan; monoclonal antibody; panitumumab; chill; digestive system cancer; fever; flushing; pruritus; rash; cancer invasion; hypotension; cd20 antigen; hematologic malignancy; nonhodgkin lymphoma; rigor; iodine 131; head and neck cancer; folinic acid; erythema; hair disease; effector cell; lung carcinoma; skin disease; flu like syndrome; dermatitis; headache; large cell lymphoma; lymphatic leukemia; corticosteroid; trastuzumab; oxaliplatin; dry skin; chronic lymphatic leukemia; tetracycline; tositumomab i 131; bacterial infection; wound healing impairment; follicular lymphoma; skin necrosis; alemtuzumab; urticaria; hematologic disease; skin ulcer; cd33 antigen; 5 fluorouracil plus oxaliplatin; cd52 antigen; cephalosporin; gemtuzumab ozogamicin; tositumomab; angioneurotic edema; antibody dependent cellular cytotoxicity; bacterial superinfection; complement dependent cytotoxicity; desquamation; eye irritation; lichenoid eruption; opportunistic infection; papular rash; paronychia; scalp hair; skin allergy; skin fissure; stevens johnson syndrome; toxic epidermal necrolysis; virus reactivation; xerosis |
| Journal Title: | Current Colorectal Cancer Reports |
| Volume: | 5 |
| Issue: | 2 |
| ISSN: | 1556-3790 |
| Publisher: | Springer |
| Date Published: | 2009-04-01 |
| Start Page: | 120 |
| End Page: | 125 |
| Language: | English |
| DOI: | 10.1007/s11888-009-0018-5 |
| PROVIDER: | scopus |
| PUBMED: | 18377777 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work